As of June 8, 2025, Catalyst Pharmaceuticals Inc (CPRX) reports a EV/EBITDA of 7.72.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Catalyst Pharmaceuticals Inc's EV/EBITDA to Peers
To better understand Catalyst Pharmaceuticals Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Catalyst Pharmaceuticals Inc (CPRX) | 7.72 |
| ADMA Biologics Inc (ADMA) | 31.05 |
| MannKind Corp (MNKD) | 22.28 |
| Abbvie Inc (ABBV) | 18.25 |
| Theratechnologies Inc (TH.TO) | 15.62 |
| Amgen Inc (AMGN) | 15.22 |
Compared to its competitors, Catalyst Pharmaceuticals Inc's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.